ArticleNucleic acids research2021
MASI: microbiota-active substance interactions database.
Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- MetaMDA: explainable prediction of microbe-drug association utilizing random walks on a microbe-metabolite-drug heterogeneous network.Bioinformatics (Oxford, England) · 2025Article
- Article
- BGMDB: A curated database linking gut microbiota dysbiosis to brain disorders.Computational and structural biotechnology journal · 2025Article
- Computational analysis of the gut microbiota-mediated drug metabolism.Computational and structural biotechnology journal · 2025Article
- GutBugDB: a web resource to predict the human gut microbiome-mediated biotransformation of biotic and xenobiotic molecules.Gut microbiome (Cambridge, England) · 2025Article
- Editorial: Omics technologies and bioinformatic tools in probiotic research.Frontiers in microbiology · 2025Article
- Predicting Disease-Metabolite Associations Based on the Metapath Aggregation of Tripartite Heterogeneous Networks.Interdisciplinary sciences, computational life sciences · 2024Article
- Probio-Ichnos: A Database of Microorganisms with In Vitro Probiotic Properties.Microorganisms · 2024Article
- Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era.Biomedicines · 2024Review
- Predicting microbe-disease association based on graph autoencoder and inductive matrix completion with multi-similarities fusion.Frontiers in microbiology · 2024Article
- Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines.Current genomics · 2024Review
- Zein as an Effective Carrier for Hesperidin Delivery Systems with Improved Prebiotic Potential.Molecules (Basel, Switzerland) · 2023Article
- The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine.Metabolites · 2023Review
- Developing a Knowledge Graph for Pharmacokinetic Natural Product-Drug Interactions.Journal of biomedical informatics · 2023Article
- CDEMI: Characterizing differences in microbial composition and function in microbiome data.Computational and structural biotechnology journal · 2023Article
- Toward FAIR Representations of Microbial Interactions.mSystems · 2022Article
- Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota.Nature reviews. Microbiology · 2022Review
- Machine learning aided construction of the quorum sensing communication network for human gut microbiota.Nature communications · 2022Article
- Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection.Journal of advanced research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xenobiotic and host active substances interact with gut microbiota to influence human health and therapeutics. Dietary, pharmaceutical, herbal and environmental substances are modified by microbiota with altered bioavailabilities, bioactivities and toxic effects. Xenobiotics also affect microbiota with health implications. Knowledge of these microbiota and active substance interactions is important for understanding microbiota-regulated functions and therapeutics. Established microbiota databases provide useful information about the microbiota-disease associations, diet and drug interventions, and microbiota modulation of drugs. However, there is insufficient information on the active substances modified by microbiota and the abundance of gut bacteria in humans. Only ∼7% drugs are covered by the established databases. To complement these databases, we developed MASI, Microbiota-Active Substance Interactions database, for providing the information about the microbiota alteration of various substances, substance alteration of microbiota, and the abundance of gut bacteria in humans. These include 1,051 pharmaceutical, 103 dietary, 119 herbal, 46 probiotic, 142 environmental substances interacting with 806 microbiota species linked to 56 diseases and 784 microbiota-disease associations. MASI covers 11 215 bacteria-pharmaceutical, 914 bacteria-herbal, 309 bacteria-dietary, 753 bacteria-environmental substance interactions and the abundance profiles of 259 bacteria species in 3465 patients and 5334 healthy individuals. MASI is freely accessible at http://www.aiddlab.com/MASI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.